Johnson & Johnson (JNJ) AI Stock Analysis

Johnson & Johnson

(BMV:JNJ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Innovative Medicine GrowthStrong growth across oncology, immunology, neuroscience, and other therapeutic areas indicates broad product adoption rather than dependence on a single medicine. Multiple expanding brands can sustain revenue momentum, support reinvestment, and help offset future product-level erosion.

Negative Factors

Margin PressureThe decline in adjusted margins shows that product mix, amortization, research spending, and transaction costs are currently absorbing part of the company’s operating leverage. Persistent pressure would reduce the amount of revenue growth converting into earnings and cash.

Johnson & Johnson (JNJ) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 657.68B
Dividend Yield: 1.73%
Average Volume (3M): 2,225
Price to Earnings (P/E): 41.4
Beta (1Y): -0.18
Revenue Growth: -3.25%
EPS Growth: -42.65%
Country: Mexico
Employees: 141,700
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Johnson & Johnson Business Overview & Revenue Model

Company Description

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses o...

Johnson & Johnson Earnings Call Summary

Earnings Call Date:Oct 12, 2026(Q3-2026)|% Change Since:7.61%|Next Earnings Date:Jan 25, 2027

Earnings Call SentimentPositive

The call was predominantly positive. Johnson & Johnson reported 6% operational sales growth, strong momentum in Innovative Medicine, significant growth from key oncology, immunology, and neuroscience brands, progress in MedTech innovation, strong cash generation, and raised 2026 guidance. These positives were partly offset by a MedTech performance shortfall, declines in Abiomed, surgery, and STELARA, lower adjusted EPS and margins, and substantial talc litigation and transaction-related charges. Management nevertheless expressed confidence in improving MedTech performance, finishing 2026 strongly, and achieving double-digit growth by the end of the decade.

Positive Updates

Q3 Sales Growth Exceeded Expectations

Worldwide sales were $25.4 billion, increasing 6% operationally and ahead of analyst consensus, with growth accelerating sequentially from the second quarter. U.S. growth was 9.1% and growth outside the U.S. was 1.8%.

Negative Updates

GAAP Earnings Were Materially Affected by Litigation and Transaction Costs

Net earnings were $210 million and diluted EPS was $0.09, compared with $2.12 a year ago. Results were affected by the proposed talc litigation resolution and expenses associated with the Firefly Bio transaction and Cell BioMedicines collaboration totaling approximately $7 billion. Adjusted net earnings were $6.3 billion and adjusted diluted EPS was $2.59, down 6.8% and 7.5%, respectively, from the third quarter of 2025.

Company Guidance

For 2026, Johnson & Johnson expects full year operational sales growth in the range of 6.7% to 7.1%, representing operational sales of $100.7 billion at the midpoint or growth of 6.9%; reported sales growth of 7.2% to 7.6%, with a midpoint of $101.2 billion or 7.4%; a decline of approximately 60 basis points in operating margin; net interest expense of $150 million to $200 million; an effective tax rate of 17.0% to 17.5%; adjusted operational earnings per share in the range of $10.95 to $11.05, or 2% at the midpoint; and reported adjusted earnings per share of $11.05 to $11.15, with a midpoint of $11.10, or growth of 2.9%. Excluding the impact of Firefly Bio and Cell BioMedicines transactions of $0.64, reported EPS growth would approach 9%; full year free cash flow guidance remains $21 billion; Firefly Bio and Cell BioMedicines are expected to have a combined dilutive impact of $1.36 per share on a full year adjusted earnings per share next year; and the company expects further acceleration in 2027, with a clear path to double digit growth by the end of the decade.

Johnson & Johnson Risk Analysis

Johnson & Johnson disclosed 23 risk factors in its most recent earnings report. Johnson & Johnson reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Johnson & Johnson Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:JNJ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PFE	74Outperform	$173.95B	40.33	4.89%	5.64%	-0.21%	-59.71%
NVS	72Outperform	$296.91B	31.19	24.24%	2.95%	1.64%	-28.72%
SNY	71Outperform	$106.82B	24.39	5.52%	5.46%	23.68%	-30.90%
GSK	67Neutral	$99.56B	17.18	24.64%	3.67%	6.93%	-18.14%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:JNJ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:JNJ	Johnson & Johnson	5167.40	1754.40	51.40%
GSK	GlaxoSmithKline	49.51	4.72	10.55%
MRK	Merck & Company	149.52	69.38	86.58%
NVS	Novartis AG	160.79	39.31	32.36%
PFE	Pfizer Inc	30.52	7.48	32.45%
SNY	Sanofi SA	44.34	-3.79	-7.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Johnson & Johnson AI Stock Analysis